Write in a clean editor, then format for Clinical Cancer Bulletin in one click — DocuGuru applies the official Springer Nature template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Clinical Cancer Bulletin is a peer-reviewed journal published by Springer Nature, covering Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Ferroptosis and cancer prognosis.
| Publisher | Springer Nature |
|---|---|
| Reference style | Superscript numbered (Nature) Superscript — small raised numerals in the text 1. Smith, A., Jones, B. & Lee, C. A representative article title. Clinical Cancer Bulletin 12, 45–58 (2023).
Formats any DOI in Clinical Cancer Bulletin style. No sign-up. |
| Publishes research in | Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Ferroptosis and cancer prognosis Lung Cancer Treatments and Mutations CAR-T cell therapy research |
| ISSN | 2791-3937 |
| Citation impact (2-yr) | 2.05 |
| h-index | 6 |
| i10-index | 3 |
| Total citations | 144 |
| Open access | Yes |
| Top institutions publishing here | Zhongshan Hospital |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Abstract Tumor research is a fundamental focus of medical science, yet the intrinsic heterogeneity and complexity of tumors present challenges in understanding their biological mechanisms of initiation, progression, and metastasis. Recent advancements in single-cell transcriptomic sequencing have revolutionized the way researchers explore tumor biology by providing unprecedented resolution. However, a key limitation of single-cell sequencing…
Abstract The liver, the largest solid organ in the body, is susceptible to metabolic diseases and malignant tumors. Studying its physiological and pathological processes helps to optimize the clinical treatment. Organoids are a novel tool for studying physical development, disease mechanisms, and high-throughput drug screening due to their similarity in composition, structure, and function to…
Abstract Chimeric antigen receptor T-cell (CAR T-cell) therapy represents a paradigm shift in treating refractory hematological malignancies. Despite its transformative potential, clinical application is frequently complicated by severe, potentially life-threatening toxicities, with cytokine release syndrome (CRS) being the most prominent. This comprehensive review synthesizes current therapeutic strategies for CRS, integrating recent advancements in multidisciplinary care…
Abstract Targeted therapy has fundamentally altered the diagnosis and treatment of clinical cancers. By focusing on chromosomal abnormalities and various indications of cancer, these medications have paved the way for the precise treatment of malignant tumors. In addition to markedly reversing the status quo of reliance on radiotherapy, chemotherapy, and surgery, these drugs have radically…
Abstract Hepatocellular carcinoma (HCC) is a malignant tumor associated with high global incidence and mortality rates. Proteomics, as a platform technology of cellular protein expression, modification, and interaction, has provided innovative perspectives on early diagnosis, treatment, and targeted drug development for HCC. This review summarizes recent progress in proteomics for advancing HCC biomarker discovery, drug…
